$GLMD
Galmed Pharmaceuticals Ltd. Stock $glmd

$glmd Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 20-F Financial Statement

#000149315223009478 Filed on March 29, 2023

Income Statement

Concept	2022 Q4	2022	2021 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.071M	$4.656M	$1.229M
YoY Change	-12.86%	-17.75%	-6.89%
% of Gross Profit
Research & Development	$1.378M	$13.00M	$6.263M
YoY Change	-78.0%	-52.26%	-30.64%
% of Gross Profit
Depreciation & Amortization	$9.000K	$35.00K	$10.00K
YoY Change	-10.0%	-16.67%	0.0%
% of Gross Profit
Operating Expenses	$2.449M	$17.65M	$7.492M
YoY Change	-67.31%	-46.32%	-27.54%
Operating Profit
YoY Change
Interest Expense	-$190.0K	-$193.0K	$40.00K
YoY Change	-575.0%	-142.23%	-42.86%
% of Operating Profit
Other Income/Expense, Net		-$215.0K
YoY Change		400.0%
Pretax Income	-$2.639M	-$17.87M	-$7.452M
YoY Change	-64.59%	-44.97%	-27.51%
Income Tax
% Of Pretax Income
Net Earnings	-$2.639M	-$17.87M	-$7.452M
YoY Change	-64.59%	-44.97%	-27.51%
Net Earnings / Revenue
Basic Earnings Per Share		$0.71
Diluted Earnings Per Share	-$0.10	-$0.71	-$297.0K
COMMON SHARES
Basic Shares Outstanding	25.20M shares	1.676M shares
Diluted Shares Outstanding		25.14M shares

Balance Sheet

Concept	2022 Q4	2022	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$13.79M	$13.79M	$34.82M
YoY Change	-60.4%	-60.4%	-31.59%
Cash & Equivalents	$2.000M	$2.016M	$2.884M
Short-Term Investments	$11.77M	$11.77M	$31.93M
Other Short-Term Assets	$114.0K	$815.0K	$114.0K
YoY Change	0.0%	-29.74%	3.64%
Inventory
Prepaid Expenses	$701.0K		$1.046M
Receivables	$825.0K		$1.125M
Other Receivables	$825.0K		$0.00
Total Short-Term Assets	$14.72M	$14.72M	$36.05M
YoY Change	-59.16%	-59.16%	-30.41%
LONG-TERM ASSETS
Property, Plant & Equipment	$114.0K	$337.0K	$551.0K
YoY Change	-79.31%	-38.84%	-3.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$1.500M	$1.500M
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$1.837M	$1.837M	$551.0K
YoY Change	233.39%	233.39%	-3.33%
TOTAL ASSETS
Total Short-Term Assets	$14.72M	$14.72M	$36.05M
Total Long-Term Assets	$1.837M	$1.837M	$551.0K
Total Assets	$16.56M	$16.56M	$36.61M
YoY Change	-54.76%	-54.76%	-30.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.560M	$2.560M	$4.871M
YoY Change	-47.44%	-47.44%	-30.91%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.094M	$3.094M	$5.879M
YoY Change	-47.37%	-47.37%	-26.6%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$44.00K	$44.00K	$229.0K
YoY Change	-80.79%	-80.79%	4.09%
Total Long-Term Liabilities	$44.00K	$44.00K	$229.0K
YoY Change	-80.79%	-80.79%	4.09%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.094M	$3.094M	$5.879M
Total Long-Term Liabilities	$44.00K	$44.00K	$229.0K
Total Liabilities	$3.138M	$3.138M	$6.108M
YoY Change	-48.62%	-48.62%	-25.78%
SHAREHOLDERS EQUITY
Retained Earnings	-$186.0M		-$168.2M
YoY Change	10.6%
Common Stock	$70.00K		$70.00K
YoY Change	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$13.42M	$13.42M	$30.50M
YoY Change
Total Liabilities & Shareholders Equity	$16.56M	$16.56M	$36.61M
YoY Change	-54.76%	-54.76%	-30.12%

Cashflow Statement

Concept	2022 Q4	2022	2021 Q4
OPERATING ACTIVITIES
Net Income	-$2.639M	-$17.87M	-$7.452M
YoY Change	-64.59%	-44.97%	-27.51%
Depreciation, Depletion And Amortization	$9.000K	$35.00K	$10.00K
YoY Change	-10.0%	-16.67%	0.0%
Cash From Operating Activities	-$4.024M	-$18.50M	-$6.990M
YoY Change	-42.43%	-43.75%	-10.84%
INVESTING ACTIVITIES
Capital Expenditures	$1.000K	$4.000K	-$1.000K
YoY Change	-200.0%	-136.36%	-90.0%
Acquisitions
YoY Change
Other Investing Activities	$1.980M	$17.57M	$6.386M
YoY Change	-68.99%	53.12%	-445.19%
Cash From Investing Activities	$1.979M	$17.56M	$6.385M
YoY Change	-69.01%	53.23%	-443.28%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00	$0.00
YoY Change		-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	$70.00K	0.000
YoY Change		-99.6%
NET CHANGE
Cash From Operating Activities	-4.024M	-$18.50M	-6.990M
Cash From Investing Activities	1.979M	$17.56M	6.385M
Cash From Financing Activities	0.000	$70.00K	0.000
Net Change In Cash	-2.045M	-$868.0K	-605.0K
YoY Change	238.02%	-78.63%	-93.76%
FREE CASH FLOW
Cash From Operating Activities	-$4.024M	-$18.50M	-$6.990M
Capital Expenditures	$1.000K	$4.000K	-$1.000K
Free Cash Flow	-$4.025M	-$18.51M	-$6.989M
YoY Change	-42.41%	-43.72%	-10.74%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001595353
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021Q4	us-gaap	Long Term Investments LongTermInvestments		usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
CY2022	GLMD	Interest Income From Shortterm Deposits InterestIncomeFromShorttermDeposits		usd
CY2022	GLMD	Increase Decrease In Restricted Deposits IncreaseDecreaseInRestrictedDeposits		usd
CY2020	GLMD	Increase Decrease In Restricted Deposits IncreaseDecreaseInRestrictedDeposits		usd
CY2021	GLMD	Payments For Proceeds From Investment In Convertible Note PaymentsForProceedsFromInvestmentInConvertibleNote		usd
CY2020	GLMD	Payments For Proceeds From Investment In Convertible Note PaymentsForProceedsFromInvestmentInConvertibleNote		usd
CY2022	us-gaap	Proceeds From Other Deposits ProceedsFromOtherDeposits		usd
CY2020	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2022Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P2Y
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	dei	Document Type DocumentType	20-F
CY2022	dei	Document Registration Statement DocumentRegistrationStatement	false
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Document Shell Company Report DocumentShellCompanyReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-36345
CY2022	dei	Entity Registrant Name EntityRegistrantName	GALMED PHARMACEUTICALS LTD.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	L3
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	16 Tiomkin Street
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Tel Aviv
CY2022	dei	Entity Address Country EntityAddressCountry	IL
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	6578317
CY2022	dei	Contact Personnel Email Address ContactPersonnelEmailAddress	[email protected]
CY2022	dei	Security12b Title Security12bTitle	Ordinary shares, par value NIS 0.01 per share
CY2022	dei	Trading Symbol TradingSymbol	GLMD
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	25203396	shares
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Document Accounting Standard DocumentAccountingStandard	U.S. GAAP
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022	dei	Auditor Firm AuditorFirmId	1197
CY2022	dei	Auditor Name AuditorName	Brightman Almagor Zohar & Co.
CY2022	dei	Auditor Location AuditorLocation	Tel Aviv, Israel
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2016000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2884000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	114000	usd
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	114000	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	11769000	usd
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	31931000	usd
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	825000	usd
CY2021Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	1125000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	14724000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	36054000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	223000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	406000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	114000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	145000	usd
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	1500000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	1837000	usd
CY2021Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	551000	usd
CY2022Q4	us-gaap	Assets Assets	16561000	usd
CY2021Q4	us-gaap	Assets Assets	36605000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2560000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4871000	usd
CY2022Q4	us-gaap	Other Loans Payable Current OtherLoansPayableCurrent	534000	usd
CY2021Q4	us-gaap	Other Loans Payable Current OtherLoansPayableCurrent	1008000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3094000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5879000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	44000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	229000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	44000	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	229000	usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25203396	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25203396	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25088414	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25088414	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	70000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	70000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	200138000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	198772000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-745000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-171000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-186040000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-168174000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	13423000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	30497000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16561000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	36605000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12995000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27220000	usd
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	26082000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4656000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5661000	usd
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4128000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	17651000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	32881000	usd
CY2020	us-gaap	Operating Expenses OperatingExpenses	30210000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-215000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	414000	usd
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1439000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-17866000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-32467000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-28771000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.71
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.32
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.35
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25142741	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24597638	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21280787	shares
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-17866000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-32467000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-28771000	usd
CY2022	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	-574000	usd
CY2021	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	-443000	usd
CY2020	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	237000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-18440000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-32910000	usd
CY2020	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-28534000	usd
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	69853000	usd
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	2066000	usd
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	61000	usd
CY2020	GLMD	Issuance Of Ordinary Shares In At The Market At Offering Net Of Issuance Costs IssuanceOfOrdinarySharesInAtTheMarketAtOfferingNetOfIssuanceCosts	707000	usd
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	237000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-28771000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	44153000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	44153000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	1886000	usd
CY2021	GLMD	Issuance Of Ordinary Shares In At The Market At Offering Net Of Issuance Costs IssuanceOfOrdinarySharesInAtTheMarketAtOfferingNetOfIssuanceCosts	8147000	usd
CY2021	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	9221000	usd
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-443000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-32467000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	30497000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	30497000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	1296000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	70000	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-574000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-17866000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	13423000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	13423000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-17866000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-32467000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-28771000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	35000	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	42000	usd
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	39000	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	-2000	usd
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	121000	usd
CY2020	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	90000	usd
CY2022	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	-523000	usd
CY2021	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	37000	usd
CY2020	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	527000	usd
CY2022	GLMD	Proceeds Finance Lease Interest Expense ProceedsFinanceLeaseInterestExpense	-36000	usd
CY2021	GLMD	Proceeds Finance Lease Interest Expense ProceedsFinanceLeaseInterestExpense	6000	usd
CY2020	GLMD	Proceeds Finance Lease Interest Expense ProceedsFinanceLeaseInterestExpense	31000	usd
CY2021	GLMD	Interest Income From Shortterm Deposits InterestIncomeFromShorttermDeposits	-7000	usd
CY2020	GLMD	Interest Income From Shortterm Deposits InterestIncomeFromShorttermDeposits	285000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	1296000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	1886000	usd
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	2066000	usd
CY2022	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-300000	usd
CY2021	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	313000	usd
CY2020	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-15000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-2311000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-2175000	usd
CY2020	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	1047000	usd
CY2022	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	-440000	usd
CY2021	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	38000	usd
CY2020	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	8000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18501000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-32892000	usd
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-26287000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	11000	usd
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	44000	usd
CY2021	GLMD	Increase Decrease In Restricted Deposits IncreaseDecreaseInRestrictedDeposits	1000	usd
CY2022	GLMD	Payments For Investment In Available For Sale Securities PaymentsForInvestmentInAvailableForSaleSecurities	2373000	usd
CY2021	GLMD	Payments For Investment In Available For Sale Securities PaymentsForInvestmentInAvailableForSaleSecurities	13569000	usd
CY2020	GLMD	Payments For Investment In Available For Sale Securities PaymentsForInvestmentInAvailableForSaleSecurities	55034000	usd
CY2022	GLMD	Payments For Proceeds From Investment In Convertible Note PaymentsForProceedsFromInvestmentInConvertibleNote	1500000	usd
CY2022	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	21440000	usd
CY2021	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	21243000	usd
CY2020	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	47198000	usd
CY2021	us-gaap	Proceeds From Other Deposits ProceedsFromOtherDeposits	3800000	usd
CY2020	us-gaap	Proceeds From Other Deposits ProceedsFromOtherDeposits	24416000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	17563000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	11462000	usd
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	16536000	usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	70000	usd
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	8147000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9221000	usd
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	707000	usd
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	61000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	70000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	17368000	usd
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	768000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-868000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4062000	usd
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-8983000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2998000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7060000	usd
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	16043000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2130000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2998000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7060000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	297000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	562000	usd
CY2020	us-gaap	Interest Paid Net InterestPaidNet	1192000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	199000	usd
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	35000	usd
CY2022	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2013-07-31
CY2022	us-gaap	Operations Commenced Date1 OperationsCommencedDate1	2014-02-02
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2000000.0	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	100000	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	11800000	usd
CY2020	us-gaap	Profit Loss ProfitLoss	-28800000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-32400000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-17900000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-186000000.0	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_841_eus-gaap--UseOfEstimates_zGC88t4TgBf6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zRbxC7nRehei">Use of estimates</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GALMED PHARMACEUTICALS LTD.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Consolidated Financial Statements</b></span></p> <div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"> </div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2 – Significant Accounting Policies (Cont.)</b></span></p>
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_848_eus-gaap--ConcentrationRiskCreditRisk_zqHMt5EWPiVb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>H.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zzLALJroNIc">Concentrations of credit risk</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments which potentially subject the Company to credit risk consist primarily of cash, cash equivalents and marketable securities. The Company hold these investments in highly-rated financial institutions, and, by policy, limit the amounts of credit exposure to any one financial institution. These amounts at times may exceed federally insured limits. The Company has not experienced any credit losses in such accounts and does not believe we are exposed to any significant credit risk on these funds. The Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts, or other hedging arrangements.</span></p>
CY2022	GLMD	Monthly Deposits Of Employees Percentage On Monthly Salary MonthlyDepositsOfEmployeesPercentageOnMonthlySalary	0.0833	pure
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	11769000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	31931000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	12514000	usd
CY2022	us-gaap	Available For Sale Debt Securities Gross Unrealized Gain AvailableForSaleDebtSecuritiesGrossUnrealizedGain	30000	usd
CY2022	us-gaap	Available For Sale Debt Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesGrossUnrealizedLoss	775000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	11769000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	32102000	usd
CY2021	us-gaap	Available For Sale Debt Securities Gross Unrealized Gain AvailableForSaleDebtSecuritiesGrossUnrealizedGain	67000	usd
CY2021	us-gaap	Available For Sale Debt Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesGrossUnrealizedLoss	238000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	31931000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	701000	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1046000	usd
CY2022Q4	GLMD	Receivables From Government Institutions ReceivablesFromGovernmentInstitutions	124000	usd
CY2021Q4	GLMD	Receivables From Government Institutions ReceivablesFromGovernmentInstitutions	79000	usd
CY2022Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	825000	usd
CY2021Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	1125000	usd
CY2022Q4	us-gaap	Area Of Land AreaOfLand	590	sqft
CY2022	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	two additional options to extend until March 22, 2023
CY2022	us-gaap	Payments For Leasing Costs PaymentsForLeasingCosts	134508	ils
CY2022	us-gaap	Cost Maintenance CostMaintenance	144476	ils
CY2022Q4	us-gaap	Lease Deposit Liability LeaseDepositLiability	50000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	223000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	216000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	406000	usd
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	435000	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y2M8D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.023	pure
CY2022Q4	us-gaap	Contractual Obligation ContractualObligation	223000	usd
CY2022Q4	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	182000	usd
CY2022Q4	us-gaap	Contractual Obligation Due In Second And Third Year ContractualObligationDueInSecondAndThirdYear	35000	usd
CY2022Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	737000	usd
CY2021Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	737000	usd
CY2022Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	54000	usd
CY2021Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	56000	usd
CY2022Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	76000	usd
CY2021Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	78000	usd
CY2022Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	235000	usd
CY2021Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	231000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1102000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1102000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	988000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	957000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	114000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	145000	usd
CY2022	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	2800000	usd
CY2021	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	4100000	usd
CY2020	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	3500000	usd
CY2022	GLMD	Bank Lien On Marketable Securities BankLienOnMarketableSecurities	114000	usd
CY2021Q2	GLMD	Upfront License Fee UpfrontLicenseFee	100000	usd
CY2020Q2	GLMD	Maximum Amount Of Shares To Be Issued Offering MaximumAmountOfSharesToBeIssuedOffering	31900000	usd
CY2021Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	18736	shares
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1000	usd
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	45000	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.16
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P10Y
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P4Y
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested	100000	usd
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	100000	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.10
CY2021Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P10Y
CY2021Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P3Y
CY2021Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested	200000	usd
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	37500	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.83
CY2021Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P10Y
CY2021Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P3Y
CY2021Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested	10000.00	usd
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	40000	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.61
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P10Y
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P4Y
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2192962	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.37
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	324784	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	200000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	333532	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	600000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12995000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27220000	usd
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	26082000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4656000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5661000	usd
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4128000	usd
CY2022	GLMD	Bank Fees BankFees	-22000	usd
CY2021	GLMD	Bank Fees BankFees	-43000	usd
CY2020	GLMD	Bank Fees BankFees	-31000	usd
CY2022	GLMD	Interest Income InterestIncome	-297000	usd
CY2021	GLMD	Interest Income InterestIncome	-562000	usd
CY2020	GLMD	Interest Income InterestIncome	-1192000	usd
CY2022	us-gaap	Debt Securities Available For Sale Gain Loss DebtSecuritiesAvailableForSaleGainLoss	526000	usd
CY2021	us-gaap	Debt Securities Available For Sale Gain Loss DebtSecuritiesAvailableForSaleGainLoss	80000	usd
CY2020	us-gaap	Debt Securities Available For Sale Gain Loss DebtSecuritiesAvailableForSaleGainLoss	-397000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-36000	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	25000	usd
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	119000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-215000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	414000	usd
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1439000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	152200000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	152000000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-17866000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-32467000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-28771000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.12	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.12	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.12	pure
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	2144000	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	3896000	usd
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	3453000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-2144000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-3896000	usd
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-3453000	usd

Files In Submission

Name	View Source	Status
0001493152-23-009478-index-headers.html	Edgar Link	pending
0001493152-23-009478-index.html	Edgar Link	pending
0001493152-23-009478.txt	Edgar Link	pending
0001493152-23-009478-xbrl.zip	Edgar Link	pending
ex1-1.htm	Edgar Link	pending
ex12-1.htm	Edgar Link	pending
ex12-2.htm	Edgar Link	pending
ex13-1.htm	Edgar Link	pending
ex15-1.htm	Edgar Link	pending
ex2-1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
form20-f.htm	Edgar Link	pending
form20f_001.jpg	Edgar Link	pending
form20f_002.jpg	Edgar Link	pending
form20f_003.jpg	Edgar Link	pending
form20f_004.jpg	Edgar Link	pending
form20f_005.jpg	Edgar Link	pending
glmd-20221231.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
form20-f_htm.xml	Edgar Link	completed
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
glmd-20221231_cal.xml	Edgar Link	unprocessable
glmd-20221231_def.xml	Edgar Link	unprocessable
glmd-20221231_lab.xml	Edgar Link	unprocessable
glmd-20221231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GLMD
Galmed Pharmaceuticals Ltd. Stock $glmd

2022 Q4 Form 20-F Financial Statement

#000149315223009478 Filed on March 29, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GLMD Galmed Pharmaceuticals Ltd. Stock $glmd

2022 Q4 Form 20-F Financial Statement

#000149315223009478 Filed on March 29, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GLMD
Galmed Pharmaceuticals Ltd. Stock $glmd